From: A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
Cycles
Reasons off treatment
1
2
3
5
6
12
Total
(n)
(%)
Disease progression
7
50
Adverse events
21
Patient withdrawal
14
Alternative therapy
Other*
4
100